Recently, at the China International Import Expo (CIIE) in Shanghai, Xiamen enterprise AmoyDx reached a collaboration agreement with Eli Lilly, a global pharmaceutical giant, to jointly promote the development of the world's first highly selective RET (short for reticulocyte) inhibitor, Selpercatinib, in China, which will benefit more RET-driven cancer patients in China. During the Expo, AmoyDx, together with AstraZeneca and other precision diagnosis ecosystem partners, founded the MET-HER2 Cancer Precision Diagnosis Alliance and jointly built an ecosystem to diagnose rare mutations in lung cancer. With a focus on clinical needs and innovative technologies, this collaboration will actively promote the implementation of innovative diagnosis schemes for related patients.
